{"symbol":"GILD","fiscalQuarter":"Q2-2025","reportDate":"2025-08-07","reportTime":"AMC","status":"reported","company":{"name":"Gilead Sciences, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/GILD/earnings/Q2-2025","postBrief":{"headline":"Gilead Sciences Beats on EPS, Stock Down N/A%","keyNumbers":[{"metric":"EPS","actual":"$2.01","expected":"N/A","surprise":"+0.80%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted ongoing investments in research and development.","They expressed confidence in the pipeline but acknowledged market challenges.","Focus remains on expanding access to existing therapies."],"summary":"Management conveyed a cautiously optimistic outlook, emphasizing the importance of their research initiatives. They recognized challenges in the market but remain committed to growth."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"This earnings report shows that Gilead Sciences was able to exceed EPS expectations, indicating some operational strength. However, the lack of revenue data and guidance leaves uncertainty about future performance. Investors will be watching closely for any updates on the company's pipeline and market strategy.","metaDescription":"Gilead Sciences (GILD) Q2 2025 earnings: EPS beat by 0.80%. Stock reaction not available. Full breakdown."}}